Impact of hematopoietic cell transplantation and quizartinib in newly diagnosed patients with acute myeloid leukemia and FMS-like tyrosine kinase 3–internal tandem duplications in the QuANTUM-First trialRichard F. Schlenk, Harry P. Erba, Mikkael A. Sekeres et al.|Haematologica|2025Cited by 7
Impact of Allogeneic Hematopoietic Cell Transplantation in First Complete Remission in Addition to FLT3 Inhibition with Quizartinib in Acute Myeloid Leukemia with <i>FLT3</i>-Internal Tandem Duplication: Results from the Quantum-First TrialRichard F. Schlenk, Harry P. Erba, Pau Montesinos et al.|Blood|2022Cited by 7
Oral Abstract: CT-186 Impact of Allogeneic Hematopoietic Cell Transplantation (allo-HCT) in First Complete Remission (CR1) in Addition to FLT3 Inhibition with Quizartinib in Acute Myeloid Leukemia (AML) with FLT3–Internal Tandem Duplication (FLT3-ITD): Results from the QuANTUM-First TrialRichard F. Schlenk, Harry P. Erba, Pau Montesinos et al.|Clinical Lymphoma Myeloma & Leukemia|2023Cited by 1
CT-186 Impact of Allogeneic Hematopoietic Cell Transplantation (allo-HCT) in First Complete Remission (CR1) in Addition to FLT3 Inhibition With Quizartinib in Acute Myeloid Leukemia (AML) With FLT3–Internal Tandem Duplication (FLT3-ITD): Results from the QuANTUM-First TrialRichard F. Schlenk, Harry P. Erba, Pau Montesinos et al.|Clinical Lymphoma Myeloma & Leukemia|2023Cited by 1
POSTER: CT-186 Impact of Allogeneic Hematopoietic Cell Transplantation (allo-HCT) in First Complete Remission (CR1) in Addition to FLT3 Inhibition With Quizartinib in Acute Myeloid Leukemia (AML) With FLT3–Internal Tandem Duplication (FLT3-ITD): Results from the QuANTUM-First TrialRichard F. Schlenk, Harry P. Erba, Pau Montesinos et al.|Clinical Lymphoma Myeloma & Leukemia|2023Cited by 0